Precigen, Inc.

Equities

PGEN

US74017N1054

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.45 USD +3.57% Intraday chart for Precigen, Inc. +0.69% +8.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Tech in Focus on -2- DJ
Precigen Shares Fall After Downgrade From JPMorgan MT
JPMorgan Downgrades Precigen to Underweight From Neutral MT
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Precigen, Inc., Q4 2023 Earnings Call, Mar 19, 2024
North American Morning Briefing : Stock Futures -2- DJ
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe MT
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission CI
Transcript : Precigen, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Precigen Q3 Net Loss Widens, Revenue Falls MT
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (PGEN) PRECIGEN Posts Q3 Revenue $1.4M MT
Transcript : Precigen, Inc. - Special Call
Insider Buy: Precigen MT
Insider Buy: Precigen MT
Transcript : Precigen, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (PGEN) PRECIGEN Reports Q2 Revenue $1.8M, vs. Street Est of $2.2M MT
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Traders Absorb -2- DJ
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval CI
Precigen, Inc.(NasdaqGS:PGEN) dropped from Russell 3000E Growth Index CI
Precigen, Inc.(NasdaqGS:PGEN) dropped from Russell 3000 Growth Index CI
Precigen, Inc.(NasdaqGS:PGEN) dropped from Russell Microcap Growth Index CI
Precigen, Inc.(NasdaqGS:PGEN) dropped from Russell 2500 Growth Index CI
Precigen, Inc.(NasdaqGS:PGEN) dropped from Russell Small Cap Comp Growth Index CI
Chart Precigen, Inc.
More charts
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company, which is advancing the gene and cell therapies using precision technology to target the urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. Its lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. AG019 ActoBiotics is a disease-modifying approach to induce antigen-specific immune tolerance to prevent, delay or reverse type-1 diabetes (T1D).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.45 USD
Average target price
9 USD
Spread / Average Target
+520.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Precigen, Inc. - Nasdaq
  4. News Precigen, Inc.
  5. After Hours Watch List Scorecard: PGEN, TYME, VRTX